Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report) CEO Marc H. Hedrick acquired 12,255 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were bought at an average price of $2.04 per share, for a total transaction of $25,000.20. Following the completion of the purchase, the chief executive officer now owns 12,425 shares in the company, valued at approximately $25,347. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Plus Therapeutics Trading Down 4.0 %
Shares of PSTV stock traded down $0.09 during trading on Friday, hitting $2.15. The company’s stock had a trading volume of 39,068 shares, compared to its average volume of 56,747. The business has a fifty day moving average of $1.83 and a 200-day moving average of $1.84. The company has a market cap of $9.19 million, a PE ratio of -0.06 and a beta of 0.55. Plus Therapeutics, Inc. has a 52 week low of $0.97 and a 52 week high of $5.09.
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last announced its earnings results on Tuesday, March 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.08. The firm had revenue of $1.31 million during the quarter, compared to analyst estimates of $1.26 million. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 271.04%. As a group, research analysts predict that Plus Therapeutics, Inc. will post -0.99 EPS for the current year.
Plus Therapeutics Company Profile
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Further Reading
- Five stocks we like better than Plus Therapeutics
- How to Calculate Options Profits
- Unity Software’s Mixed Q1, But Long-Term Outlook Remains Positive
- Overbought Stocks Explained: Should You Trade Them?
- JFrog Stock Gets Punished for Solid Results: Buy the Dip
- Why Invest in High-Yield Dividend Stocks?
- Will the Surge in GameStop Stock Spark a New Meme Craze?
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
